InsidersTradesSigma
Total declarations
Company
▲ Purchases (15 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by Jones James, Director. Director active across 1 companies, notably Cumberland Pharmaceuticals INC. In total, 18 reports have been published. Total volume traded: €1k. The latest transaction was filed on 1 June 2022 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations18 total
€7338 shares@ €1.92410.0001% mcap0.8% of flow
Common Stock
SEC:0001209191-22-040104:0·
Ideal exit: 26 Feb 2023 (T+270)
€7030 shares@ €2.33130.0001% mcap0.8% of flow
Common Stock
SEC:0001209191-22-036001:0·
Ideal exit: 27 Jan 2023 (T+270)
€7028 shares@ €2.50440.0001% mcap0.8% of flow
Common Stock
SEC:0001209191-22-027649:0·
Ideal exit: 9 Jan 2023 (T+270)
€2,3611,000 shares@ €2.36110.0029% mcap25.7% of flow
Common Stock
SEC:0001209191-22-026146:0·
€7721 shares@ €3.65390.0001% mcap2.3% of flow
Common Stock
SEC:0001209191-22-002468·
Ideal exit: 28 Aug 2022 (T+270)
€7721 shares@ €3.65390.0001% mcap0.8% of flow
Common Stock
SEC:0001209191-22-002468:0·
Ideal exit: 28 Aug 2022 (T+270)
€9742 shares@ €2.31040.0001% mcap2.9% of flow
Common Stock
SEC:0001209191-21-067893·
Ideal exit: 29 Jul 2022 (T+270)
€9742 shares@ €2.31040.0001% mcap1.1% of flow
Common Stock
SEC:0001209191-21-067893:0·
Ideal exit: 29 Jul 2022 (T+270)
€9842 shares@ €2.32410.0001% mcap2.9% of flow
Common Stock
SEC:0001209191-21-063228·
Ideal exit: 28 Jun 2022 (T+270)
€9842 shares@ €2.32410.0001% mcap1.1% of flow
Common Stock
SEC:0001209191-21-063228:0·
Ideal exit: 28 Jun 2022 (T+270)
€10242 shares@ €2.43220.0001% mcap3.1% of flow
Common Stock
SEC:0001209191-21-058527·
Ideal exit: 29 May 2022 (T+270)
€10242 shares@ €2.43220.0001% mcap1.1% of flow
Common Stock
SEC:0001209191-21-058527:0·
Ideal exit: 29 May 2022 (T+270)
€11842 shares@ €2.81270.0001% mcap3.6% of flow
Common Stock
SEC:0001209191-21-055483·
Ideal exit: 29 Apr 2022 (T+270)
€11842 shares@ €2.81270.0001% mcap1.3% of flow
Common Stock
SEC:0001209191-21-055483:0·
Ideal exit: 29 Apr 2022 (T+270)
€11342 shares@ €2.6840.0001% mcap3.4% of flow
Common Stock
SEC:0001209191-21-051438·
Ideal exit: 4 Apr 2022 (T+270)
€11342 shares@ €2.6840.0001% mcap1.2% of flow
Common Stock
SEC:0001209191-21-051438:0·
Ideal exit: 4 Apr 2022 (T+270)
€2,7061,000 shares@ €2.70550.0033% mcap81.7% of flow
Common Stock
SEC:0001209191-21-039936·
€2,7061,000 shares@ €2.70550.0033% mcap29.4% of flow
Common Stock
SEC:0001209191-21-039936:0·
18 of 18 declarations
About Jones James
James Jones is an executive at CUMBERLAND PHARMACEUTICALS INC.
